GHRP-6 [Nasal Spray]

Description

What is GHRP-6 Nasal Spray?

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GHS-R1a agonist developed by Cyril Y. Bowers at Tulane University in 1984. It was the first compound in the GHRP family and contains two D-amino acids (D-Trp², D-Phe⁵) that improve metabolic stability. It acts at the growth hormone secretagogue receptor 1a (GHS-R1a), later identified as the ghrelin receptor in 1999. A distinguishing feature among GHRPs is its potent orexigenic activity via arcuate nucleus NPY/AgRP neurons. GHRP-6 has not been approved as a registered pharmaceutical in any country.

The compound has been investigated in rat, ovine, porcine, and transfected cell preparations for GHS-R1a-mediated GH secretion and hypothalamic arcuate nucleus activation. The nasal spray formulation is studied as a preclinical research delivery route. Intranasal delivery of GHRP-6 has been shown to engage the brain GHS-R signaling system in mouse arcuate nucleus preparations [Poelman et al., 2025; PMID 39813130]. It also bypasses hepatic first-pass metabolism relative to systemic routes in preclinical pharmacokinetic models.

DISCLAIMER: GHRP-6 Nasal Spray has not been approved by the Food and Drug Administration for human use, consumption, or any therapeutic application. This product is supplied exclusively for in vitro and preclinical laboratory research purposes.

Chemical Properties of GHRP-6

How Does GHRP-6 Work?

GHRP-6 acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), a Gq-protein-coupled receptor expressed on anterior pituitary somatotroph cells and on hypothalamic neurons, notably NPY/AgRP neurons in the arcuate nucleus. Receptor engagement activates the phospholipase C (PLC)/inositol 1,4,5-trisphosphate (IP₃)/intracellular Ca²⁺ signaling cascade, driving GH secretory granule release. Critically, GHRP-6 stimulates GH release without increasing intracellular cAMP, distinguishing its mechanism from GHRH-R-mediated signaling. The following mechanistic observations are from preclinical and in vitro data only.

GHS-R1a Binding and Ca²⁺-Dependent GH Release

GHRP-6 binds GHS-R1a with high affinity (Ki approximately 1.9 nM at human GHS-R1a in transfected COS-7 cell preparations). Receptor engagement does not increase intracellular cAMP in either rat or ovine somatotroph preparations, distinguishing GHRP-6 from GHRH-R agonists. GH release was fully dependent on extracellular Ca²⁺ influx – Ca²⁺ channel blockade completely prevented GH secretion in ovine and rat somatotroph preparations [Wu et al., 1996; PMID 8699133]. Somatostatin suppressed GH release in response to GHRP-6 in these preparations.

Dual Site of Action: Pituitary and Hypothalamus

GHRP-6 operates via a dual mechanism: a direct pituitary somatotroph action via GHS-R1a engagement, and a hypothalamic action. At the pituitary level, GHRP-6 stimulates GH release independently of cAMP. At the hypothalamic level, GHRP-6 does not inhibit somatostatin (SRIF) release, distinguishing its hypothalamic action from opioid peptides. GHRP-6 and GHRH produce synergistic GH release in combined in vitro and in vivo rat preparations, consistent with independent receptor systems [Bowers et al., 1991; PMID 2004615].

GHS-R1a/PLC/IP₃/Ca²⁺ Signaling Cascade

In dispersed porcine pituitary somatotroph preparations, GHS-R agonism increased intracellular Ca²⁺ concentration ([Ca²⁺]i) in a dose-dependent manner. This Ca²⁺ elevation was attenuated by the GHS-R-specific antagonist (D-Lys³)-GHRP-6, blocked by the L-type calcium channel antagonist nifedipine, and partially reduced by inhibitors of both adenylyl cyclase (SQ-22536) and phospholipase C (U73122), indicating involvement of both the PLC/IP₃ and cAMP pathways [Glavaski-Joksimovic et al., 2003; PMID 12845223].

Hypothalamic Arcuate Nucleus Activation via Intranasal Route

Intranasal GHRP-6 at 5 mg/kg in C57BL/6 mice engaged brain GHS-R signaling pathways. Fos mapping of the arcuate nucleus showed elevated neuronal activation relative to saline controls. RNAscope analysis of c-fos mRNA-expressing neurons revealed coexpression with Ghsr mRNA (63.5 ± 1.9%), Agrp mRNA (79 ± 6.8%), and Ghrh mRNA (11.4 ± 2.5%), confirming intranasal GHRP-6 engages arcuate nucleus neurons involved in GH axis regulation and orexigenic signaling [Poelman et al., 2025; PMID 39813130].

Intranasal Delivery & Pharmacokinetics

Olfactory Bulb-Mediated CNS Transport

When administered intranasally in preclinical rodent model systems, peptide compounds can access the central nervous system through the olfactory nerve (cranial nerve I) pathway. Compounds deposited on the olfactory mucosa are transported along olfactory axons through the cribriform plate to the olfactory bulb, from which access to deeper CNS structures has been characterized in rodent preparations. For GHRP-6 specifically, intranasal administration in C57BL/6 mice produced measurable arcuate nucleus neuronal activation and elevated serum GH, providing direct preclinical evidence that the intranasal route engages the brain GHS-R signaling system [Poelman et al., 2025; PMID 39813130]. This makes GHRP-6 one of a small number of RCDbio nasal spray research compounds with published compound-specific intranasal CNS delivery evidence.

Hepatic First-Pass Metabolism Bypass

The intranasal route avoids portal circulation and hepatic first-pass metabolic processing. GHRP-6 has an oral bioavailability of less than 1% due to rapid proteolytic degradation in the GI environment. The presence of D-amino acids (D-Trp², D-Phe⁵) improves resistance to aminopeptidase activity at the nasal mucosa relative to all-L-amino acid peptides. These observations are derived from preclinical studies and do not constitute evidence of efficacy via any route in human subjects.

Nasal Mucosal Absorption

GHRP-6 has a molar mass of 873.03 g/mol (approximately 0.87 kDa). This molecular weight falls below the 1 kDa threshold, indicating transcellular diffusion is a plausible absorption mechanism at the nasal mucosa alongside paracellular transport. The D-amino acid substitutions and compact hexapeptide structure are consistent with improved nasal mucosal stability relative to linear L-amino acid peptides. Specific nasal mucosal permeability coefficients for GHRP-6 have not been formally characterized in published preclinical models.

Compound-Specific Pharmacokinetics

The Poelman et al. 2025 study (PMID 39813130) demonstrates CNS engagement following intranasal administration in mice at 5 mg/kg but does not report formal systemic PK parameters (Cmax, Tmax, AUC, half-life) for the intranasal route. The reported elimination half-life of approximately 2.5 hours is derived from systemic (non-intranasal) administration data. Researchers should account for the absence of intranasal-specific pharmacokinetic parameters when designing dosing protocols.

Key Research Findings

Intranasal GHRP-6 Arcuate Nucleus Activation (C57BL/6 Mouse): Intranasal GHRP-6 (5 mg/kg) increased food intake, elevated serum GH, and produced Fos activation in arcuate nucleus neurons; c-fos-expressing neurons coexpressed Ghsr mRNA (63.5%), Agrp mRNA (79%), and Ghrh mRNA (11.4%), confirming engagement of the brain GHS-R signaling system via intranasal delivery [Poelman et al., 2025; PMID 39813130]

GH Release Without cAMP Elevation (Ovine and Rat Somatotroph Preparations): GHRP-6 stimulated GH release in ovine and rat pituitary cell preparations without increasing intracellular cAMP; GH secretion was fully blocked by Ca²⁺ channel blockade, confirming a cAMP-independent, Ca²⁺-dependent mechanism distinct from GHRH-R signaling [Wu et al., 1996; PMID 8699133]

Dual Hypothalamic-Pituitary Site of Action (Rat Preparations): GHRP-6 released GH via independent, non-GHRH and non-opioid receptor pathways at both the hypothalamus and pituitary in rat preparations; synergistic GH release with GHRH confirmed independent receptor systems; GHRP-6 did not inhibit hypothalamic SRIF release [Bowers et al., 1991; PMID 2004615]

GHS-R PLC/IP₃/Ca²⁺ Signaling (Porcine Somatotroph Preparation): GHS-R agonism increased intracellular Ca²⁺ in a dose-dependent manner in dispersed porcine somatotroph preparations; response was blocked by L-type calcium channel blockade and attenuated by both PLC and adenylyl cyclase inhibition [Glavaski-Joksimovic et al., 2003; PMID 12845223]

All findings listed above are derived from preclinical in vitro and in vivo model systems using mouse, rat, ovine, and porcine preparations. These observations do not constitute evidence of efficacy or safety for GHRP-6 nasal spray in any organism. No human clinical data has been established for research-grade GHRP-6 administered via the intranasal route.

What are the Potential Research Applications?

In controlled laboratory environments, GHRP-6 nasal spray has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

GHS-R1a Receptor Binding and Signaling Research

GHRP-6 is a well-characterized GHS-R1a reference agonist used in competitive binding assays, receptor occupancy studies, and intracellular Ca²⁺ mobilization experiments in cell preparations expressing human GHS-R1a. Research applications include characterization of GHS-R1a-mediated PLC/IP₃/Ca²⁺ signaling, (D-Lys³)-GHRP-6 antagonist studies, and comparative pharmacology with ghrelin, GHRP-2, and ipamorelin in transfected cell systems.

Intranasal CNS Delivery Research

GHRP-6 is one of a small number of research peptides with published intranasal CNS engagement data. It serves as a positive control for intranasal GHS-R delivery experiments in rodent model systems. Research applications include arcuate nucleus Fos mapping following intranasal administration, dose-finding for intranasal GHS-R engagement, and comparison of intranasal versus systemic GHS-R activation profiles in mouse and rat preparations.

Hypothalamic Circuit Research

In preclinical mouse and rat models, GHRP-6 has been used to study GHS-R1a-expressing hypothalamic neuronal circuits, including NPY/AgRP-expressing arcuate nucleus neurons and their downstream effects on GH pulsatility and feeding behavior. Applications include c-fos mRNA coexpression studies using RNAscope, neuropeptide expression profiling, and examination of arcuate-pituitary axis interactions in preclinical model systems.

Orexigenic Signaling Research

GHRP-6’s potent orexigenic activity via arcuate NPY/AgRP neuron engagement makes it a tool compound for studying central appetite and energy homeostasis signaling in preclinical preparations. Research applications include meal pattern analysis following GHS-R1a engagement via the intranasal route, comparative orexigenic profiling against ghrelin and MK-0677, and arcuate-hypothalamic circuit characterization in mouse model systems.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized, and no human safety data has been established for the research-grade nasal spray formulation.

• Cortisol and prolactin elevation (preclinical and investigational data): GHRP-6 at higher doses has been associated with elevations in ACTH, cortisol, and prolactin in addition to GH release in preclinical and investigational study preparations; these observations are dose-dependent and distinct from the GH-releasing effect [Correa-Silva et al., 2006; PMID 16832586]
• Potent orexigenic activity (preclinical): GHRP-6 produced significant increases in food intake, meal frequency, and meal size in C57BL/6 mouse preparations following intranasal administration at 5 mg/kg; inadvertent intranasal self-exposure during laboratory handling may produce appetite-stimulating CNS effects [Poelman et al., 2025; PMID 39813130]
• GH axis desensitization (preclinical class data): Repeated administration of GHS-R1a agonists in preclinical models has been associated with receptor desensitization and attenuation of GH secretory responses; the time course for intranasal GHRP-6 specifically has not been characterized
• Somatostatin feedback modulation (preclinical): GHRP-6 modulates hypothalamic somatostatin feedback regulation in preclinical preparations; repeated GHS-R1a engagement may alter the normal somatostatin/GHRH pulsatile GH regulatory circuit in rodent model systems
• Absence of intranasal safety data: While compound-specific intranasal CNS engagement data exists, no formal safety or tolerability data specific to the intranasal route of administration for GHRP-6 has been published as of June 2026

No human safety or tolerability data has been established for GHRP-6 nasal spray. These observations are derived from experimental systems and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific precautions apply:

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. CNS-active compounds may produce pharmacological effects via inadvertent intranasal self-exposure.
2. Handle the nasal spray solution in a clean laboratory environment. For aliquoting or analytical sampling, use a laminar flow cabinet.
3. The nasal spray solution is an aqueous formulation susceptible to microbial contamination if compromised. Handle under aseptic conditions. Discard if the solution appears cloudy, discolored, or shows particulate matter.
4. Avoid aerosol generation during any manipulation of the nasal spray solution.

Exposure Risks

Risk Tier: LOW–MODERATE

GHRP-6 acts as a GHS-R1a agonist with documented CNS engagement via the intranasal route in preclinical mouse preparations. Inadvertent intranasal self-exposure during laboratory handling carries a risk of appetite stimulation, transient GH axis modulation, and potential cortisol/prolactin elevation at higher exposure levels. The compound’s potent orexigenic activity is a specific handling consideration. No human safety or tolerability data has been established for GHRP-6 nasal spray. Researchers should handle this compound with precautions appropriate to a CNS-active peptide with confirmed intranasal biological activity.

Storage

In-use nasal spray: Store at 2–8°C. Use within 28 days of first actuation. Protect from light. Keep upright.

DO NOT FREEZE the ready-to-use nasal spray formulation. Freezing alters pH, buffer stability, excipient integrity, and spray actuation properties.

Lyophilized bulk stock (if applicable): Store at −20°C in sealed, desiccated, light-protected containers. Avoid repeated freeze-thaw cycles.

Discard any solution that appears cloudy, discolored, or shows visible particulate matter.

FAQs

Q: How does intranasal administration facilitate CNS access for GHRP-6 in preclinical research models?

A: GHRP-6 has published compound-specific intranasal CNS delivery data. Intranasal GHRP-6 at 5 mg/kg in C57BL/6 mice produced Fos activation in arcuate nucleus neurons, elevated serum GH, and increased food intake, confirming engagement of the brain GHS-R signaling system [Poelman et al., 2025; PMID 39813130]. Activated arcuate neurons coexpressed Ghsr, Agrp, and Ghrh mRNA, confirming neurochemical specificity. Intranasal delivery also bypasses hepatic first-pass metabolism. No human CNS delivery data has been established for research-grade GHRP-6 nasal spray.

Q: What is the recommended storage and in-use shelf life for GHRP-6 nasal spray?

A: Sealed product should be stored at 2–8°C, protected from light. Once first actuated, in-use shelf life is 28 days at 2–8°C. DO NOT FREEZE the ready-to-use solution – freezing destabilizes the buffer, alters pH, and may damage spray actuation. Lyophilized bulk stock should be stored at −20°C in sealed, desiccated, light-protected conditions. Discard if the solution shows cloudiness, discoloration, or particulate matter.

Q: Is the GHRP-6 nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in isotonic saline (0.9% NaCl, pH 4.5–5.5) without preservatives. The preservative-free composition reduces cytotoxicity risk in sensitive cell preparations relative to preserved formulations. Researchers should validate the vehicle independently in their specific cell system. The formulation pH is below the typical cell culture range; dilution into culture medium before application is recommended. Researchers are responsible for confirming compatibility with their assay system.

Q: What is the plasma half-life of GHRP-6 in preclinical models?

A: The elimination half-life of GHRP-6 following systemic administration is approximately 2.5 hours. Oral bioavailability is less than 1%. D-amino acid substitutions at positions 2 and 5 confer partial aminopeptidase resistance. No formal intranasal pharmacokinetic parameters have been published as of June 2026.

Q: How does GHRP-6 differ from GHRP-2, ipamorelin, and ghrelin?

A: All four are GHS-R1a agonists. GHRP-6 has the strongest orexigenic activity among synthetic GHRPs. GHRP-2 has greater GH-releasing potency with reduced appetite stimulation. Ipamorelin is a selective pentapeptide with minimal effect on cortisol, prolactin, or appetite. Ghrelin is the endogenous 28-amino acid GHS-R1a ligand. GHRP-6 uniquely stimulates GH release without increasing intracellular cAMP, via a Ca2+/PLC/IP3-dependent mechanism distinct from GHRH analogs.

Q: What is the WADA status of GHRP-6?

A: GHRP-6 is explicitly named on the 2026 WADA Prohibited List under Category S2.2.4 (Growth Hormone Releasing Factors), listed among GH-releasing peptides including GHRP-1 through GHRP-6.  It is prohibited both in and out of competition for all WADA Code signatories. RCDbio products are supplied for laboratory research purposes only and are not supplied for use in competitive sport contexts.

Q: What toxicity observations have been reported for GHRP-6?

A: At higher doses in preclinical preparations, GHRP-6 has been associated with cortisol and prolactin elevation in addition to GH release. Potent orexigenic effects have been documented following both systemic and intranasal administration in mouse and rat preparations. No formal toxicology studies for the intranasal route are available. No human safety or tolerability data has been established for GHRP-6 nasal spray.

Related Research Compounds

Researchers investigating GHRP-6 nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

Ipamorelin Nasal Spray – A selective GHS-R1a agonist pentapeptide investigated in preclinical models for GH secretagogue activity with reduced cortisol and prolactin co-stimulation relative to GHRP-6.

GHRP-2 Nasal Spray – A second-generation synthetic hexapeptide GHS-R1a agonist investigated in preclinical somatotroph preparations for potent GH-releasing activity and comparative mechanistic studies with GHRP-6.

CJC-1295 With DAC Nasal Spray – A long-acting GHRH analog investigated for GHRH-R/cAMP-mediated GH axis modulation via a complementary receptor pathway; used in combination with mechanistic studies with GHS-R1a agonists in preclinical preparations.

All products listed are for laboratory and research purposes only.

References

1. Poelman, R., Le May, M.V., Schéle, E., Stoltenborg, I., & Dickson, S.L. (2025). Intranasal delivery of a ghrelin mimetic engages the brain ghrelin signaling system in mice. Endocrinology, 166(3).

   https://pubmed.ncbi.nlm.nih.gov/39813130/

2. Wu, D., Chen, C., Zhang, J., Bowers, C.Y., & Clarke, I.J. (1996). The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′,5′-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. Journal of Endocrinology, 148(2), 197–205.

   https://pubmed.ncbi.nlm.nih.gov/8699133/

3. Bowers, C.Y., Sartor, A.O., Reynolds, G.A., & Badger, T.M. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027–2035.

   https://pubmed.ncbi.nlm.nih.gov/2004615/

4. Glavaski-Joksimovic, A., Jeftinija, K., Scanes, C.G., Anderson, L.L., & Jeftinija, S. (2003). Stimulatory effect of ghrelin on isolated porcine somatotropes. Neuroendocrinology, 77(6), 367–379.

   https://pubmed.ncbi.nlm.nih.gov/12845223/

Disclaimer

GHRP-6 Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co